Business Wire

FlexTrade Implements Machine Learning for Real-time Market Impact Analytics

11.5.2022 11:14:00 EEST | Business Wire | Press release

Share

FlexTrade Systems, a global leader in multi-asset execution and order management systems, today announced the launch of machine-learning driven real-time market impact analytics, which are now available within FlexTRADER EMS.

This analytics enhancement comes as the industry calls for solutions providers to increase innovation and deliver actionable analytics to help improve decision-making and reduce market impact on the buy-side trading desk. FlexTrade's in-house data science team has driven the new initiative and refined it further through input and collaboration with clients.

FlexTrade's market impact analytics are generated by applying a proprietary neural network model to a large corpus of order data to help investment managers understand the performance of their execution strategies. The solution allows traders to see an estimate of their current and realized market impact in real-time, meaning strategies can be monitored and adjusted automatically based on market conditions. Traders using the solution can also leverage data visualization to understand how the market impact has changed over the life of the order, including any increases or decreases as more volume is traded or when an order is finished or paused. Further, the new offering, deeply integrated directly within the FlexTRADER EMS order blotter, can be viewed holistically alongside third-party analytics to deliver increased transparency, improved trading decision-making and assist with best execution obligations.

FlexTrade's real-time machine-learning driven market impact analytics are available immediately for deployment, with the first client, an EMEA based Tier 1 buy-side asset manager, live in production. FlexTrade will showcase the new analytics offering this month at WBR's TradeTech Europe in Paris on the 11th and 12th of May.

Andy Mahoney, Managing Director, EMEA at FlexTrade, noted : "Designing and delivering ground-breaking innovation is at the core of what we do at FlexTrade. Leveraging new technologies such as machine learning ensures FlexTrade's clients can take advantage of unique, actionable insights to drive their trading in real-time. At a time when the industry is calling for innovation to return following a lull, understandably, caused by the pandemic, we are at the front of the pack offering disruptive technologies led initiatives - rapidly delivered to the market and our clients - that add real tangible value to their execution strategies."

About FlexTrade

Founded in 1996, FlexTrade Systems is the global leader in high performance execution management and order management systems for equities, foreign exchange, options, futures, and fixed income.

A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER, the world's first broker-neutral, and execution management trading system, which allows clients to completely control and customize their proprietary algorithms while maintaining the confidentiality of their trading strategies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Iain Smith
Iain.Smith@FlexTrade.com
o: +44 20 3757 9311 x 9311

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 05:30:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for a global leader in healthcare services. This resulted in faster time to market, modern scalable ecosys

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye